MedPage Today (3/16, Robertson) reports a study found that “extended-release buprenorphine was an effective treatment for pregnant women with opioid use disorder (OUD) and safe for their babies.” Researchers observed that “women randomized to weekly, injectable extended-release buprenorphine had higher rates of abstinence from illicit opioids than those in the sublingual buprenorphine group (82.5% vs 72.6%).” Furthermore, “those taking extended-release buprenorphine also had fewer serious adverse events during pregnancy (8.7% vs 26.8%) and during the postpartum period (6% vs 18.6%). While rates of nonserious AEs did not differ between groups, more were considered related to extended-release buprenorphine during pregnancy (26.1% vs 7%),” although they “were mostly mild.” The study was published in JAMA Internal Medicine.
Related Links:
— MedPage Today (requires login and subscription)